Pfenex Inc (NASDAQ:PFNX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Friday, MarketBeat.Com reports. According to Zacks, “Pfenex Inc. is a clinical-stage biotechnology company developing and commercializing proteins. The company’s lead product candidate is PF582, a biosimilar candidate to Lucentis, for the potential treatment […]
